BindingDB

The first public molecular recognition database, BindingDB supports research, education and practice in drug discovery, pharmacology and related fields.

BindingDB contains 3.2M data for 1.4M Compounds and 11.4K Targets. Of those, 1.6M data for 756K Compounds and 4.8K Targets were curated by BindingDB curators. BindingDB is a FAIRsharing resource.

If BindingDB was of value to your research, please take a moment to donate to this nonprofit project. Your donation will let us provide you with more data and improved service.

Donate Now

To help with training and testing AI and other models, BindingDB downloads and search results now provide the publication date and BindingDB curation date of each measurement.

Advanced Search

31 articles for MJ Orwat

The following articles (labelled with PubMed ID or TBD) are for your review

PMID
Data
Article Title
Organization
Orally bioavailable pyridine and pyrimidine-based Factor XIa inhibitors: Discovery of the methyl N-phenyl carbamate P2 prime group.EBI
Bristol-Myers Squibb
Novel phenylalanine derived diamides as Factor XIa inhibitors.EBI
Bristol-Myers Squibb
Orally bioavailable factor Xa inhibitors containing alpha-substituted gem-dimethyl P4 moieties.EBI
Bristol-Myers Squibb
Structure-activity relationship and pharmacokinetic profile of 5-ketopyrazole factor Xa inhibitors.EBI
Bristol-Myers Squibb Research and Development
Discovery of 1-[3-(aminomethyl)phenyl]-N-3-fluoro-2'-(methylsulfonyl)-[1,1'-biphenyl]-4-yl]-3-(trifluoromethyl)-1H-pyrazole-5-carboxamide (DPC423), a highly potent, selective, and orally bioavailable inhibitor of blood coagulation factor Xa.EBI
Dupont Pharmaceuticals
Discovery of an orally active series of isoxazoline glycoprotein IIb/IIIa antagonists.EBI
Dupont Pharmaceuticals
 
Chemistry and pharmacokinetics of diarylthiophenes and terphenyls as selective COX-2 inhibitorsEBI
TBA
 
Immunosuppressive structure-activity relationships of Brequinar and related cinchoninic acid derivativesEBI
TBA
Synthesis and SAR of benzamidine factor Xa inhibitors containing a vicinally-substituted heterocyclic core.EBI
Dupont Pharmaceuticals
Structure based design of macrocyclic factor XIa inhibitors: Discovery of cyclic P1 linker moieties with improved oral bioavailability.EBI
Bristol-Myers Squibb
Terphenyl cyclooxygenase-2 (COX-2) inhibitors: optimization of the central ring and o-biphenyl analogs.EBI
Dupont Pharmaceuticals
Orally active isoxazoline glycoprotein IIb/IIIa antagonists with extended duration of action.EBI
Dupont Pharmaceuticals
Structure-activity relationships (SAR) of some tetracyclic heterocycles related to the immunosuppressive agent Brequinar Sodium.EBI
Dupont Pharmaceuticals
Discovery of a Parenteral Small Molecule Coagulation Factor XIa Inhibitor Clinical Candidate (BMS-962212).EBI
Bristol-Myers Squibb
SOS1 Inhibitor With Pyrido-Fused Six-Membered Ring StructureBDB
Haihe Biopharma Co.
Heteroaryl compounds as BTK inhibitors and uses thereofBDB
Merck Patent
4-cyano-benzyl carbamimidoylcarbamate derivatives and their use as AOC3 inhibitorsBDB
Boehringer Ingelheim International
Crystalline forms of a PI3K inhibitorBDB
Incyte
Modulators of ATP-binding cassette transportersBDB
Vertex Pharmaceuticals
Soluble guanylate cyclase stimulatorsBDB
Merck Sharp & Dohme
Compounds and uses BDB
Astrazeneca
Evaluation of cancer dependence and druggability of PRP4 kinase using cellular, biochemical, and structural approaches.BDB
Sanofi Oncology
Phosphatidylinositol 3-kinase inhibitorsBDB
Gilead Calistoga
Substituted bicyclic 1-carboxylic-acid (benzyl-cyano-methyl)-amides inhibitors of cathepsin CBDB
Boehringer Ingelheim International
Pyrimidine derivatives that inhibit FAK/PTK2BDB
Boehringer Ingelheim International
3H-imidazo [4, 5-C] pyridine-6-carboxamides as anti-inflammatory agentsBDB
Boehringer Ingelheim International
SGLT-2 inhibitors, methods of making them, and uses thereofBDB
Albany Molecular Research
[3H]-Mesulergine labels 5-HT7 sites in rat brain and guinea-pig ileum but not rat jejunum.BDB
Monash University
Nonpeptide tachykinin receptor antagonists: I. Pharmacological and pharmacokinetic characterization of SB 223412, a novel, potent and selective neurokinin-3 receptor antagonist.BDB
Smithkline Beecham Pharmaceuticals
Aloisines, a new family of CDK/GSK-3 inhibitors. SAR study, crystal structure in complex with CDK2, enzyme selectivity, and cellular effects.BDB
Faculte De Medecine Et De Pharmacie